RNS, new shares23 Jan 2023 12:40
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces it has issued and allotted a total of 3,068,421 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares"). The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.75 million and interest repayment of £0.89 million in respect of the Company's unsecured convertible bond, as detailed in Avacta's announcement on 18 October 2022.
After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.75 million to £52.25 million.